Cybin D/B/A Helus Pharma HELP
Set alert
10.60 USD -0.12 -1.07%
At close · Oct 30
10.50 -0.10 -0.90%
After hours · Oct 30, 7:54 PM ET
10.42 Day range 10.97
3.87 52-week range 14.02
- YTD
- +29.52%
- 1 year
- +47.56%
- Open
- 10.53
- Prev close
- 10.71
- Mkt cap
- 774.17M
- Vol
- 1.15M
- Avg vol
- 1.70M
- EPS
- -4.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.42
- High
- 10.97
- Forward P/E
- -7.55
- Beta
- 0.63
- Short ratio
- 1.59
- Inst. own
- 41.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 10.70
- 200-d avg
- 7.11
- 1y target
- 40.24
3M chart
Events in this range
- Aug 14, 2026Earnings: -0.91; estimate -0.83607; surprise -8.84%
- Aug 20, 2026Rating: TD Cowen · Buy → Buy
- Sep 18, 2026Rating: Barclays · — → Overweight
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| RSI: Overbought | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
Financial health
Altman Z-Score
27.56 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
Valuation
P/E -1.1×
FY 2017 5y median -1.1× FY 2026
P/S -3.7×
FY 2017 5y median 155× FY 2026
P/B 0.7×
FY 2017 5y median 0.7× FY 2026
P/FCF -1.2×
FY 2017 5y median -1.2× FY 2026
EV/EBITDA -0.1×
FY 2017 5y median -0.1× FY 2026
EV/Sales -0.2×
FY 2017 5y median 0.0× FY 2026
FCF Yield -80.1%
FY 2017 5y median -80.1% FY 2026
Profitability
Gross Margin 100.3%
FY 2017 5y median 0.0% FY 2026
Operating Margin 317.1%
FY 2017 5y median -20523.9% FY 2026
Net Margin 329.1%
FY 2017 5y median -18919.2% FY 2026
ROE -63.3%
FY 2017 5y median -63.3% FY 2026
ROIC -60.9%
FY 2017 5y median -60.9% FY 2026
ROA -58.4%
FY 2017 5y median -58.4% FY 2026
Growth (YoY)
Revenue -9561.6%
FY 2017 FY 2026
Operating Income 1.0%
FY 2017 FY 2026
EPS (diluted) 24.3%
FY 2017 FY 2026
Free Cash Flow -29.6%
FY 2017 FY 2026
Financial Health
Current Ratio 9.5×
FY 2017 5y median 7.7× FY 2026
Quick Ratio 9.5×
FY 2017 5y median 7.7× FY 2026
Debt / Equity 0.0×
FY 2017 5y median 0.0× FY 2026
Net Debt / EBITDA 1.1×
FY 2017 5y median 0.9× FY 2026
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2026
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2026
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2026
Annual · latest fiscal year ends 2026-03-31